Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs. Issue 3 (12th July 2018)

• Record Type: Journal Article
• Authors: Gadina, Massimo; Johnson, Catrina; Schwartz, Daniella; Bonelli, Michael; Hasni, Sarfaraz; Kanno, Yuka; Changelian, Paul; Laurence, Arian; O'Shea, John J.
• Other Names: Ivashkiv Lionel guestEditor.; Li Liwu guestEditor.; Hu Xiaoyu guestEditor.
• Is Part Of: Journal of leukocyte biology. Volume 104:Issue 3(2018)
• Page Start: 499
• Page End: 514
• Publication Date: 2018-07-12
• Subjects: autoimmunity -- cytokines -- cytokine signaling -- Janus kinase -- STATs; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.5RI0218-084R
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: In this era, it is axiomatic that cytokines have critical roles in cellular development and differentiation, immune homeostasis, and host defense. Equally, dysregulation of cytokines is known to contribute to diverse inflammatory and immune‐mediated disorders. In fact, the past 20 years have witnessed the rapid translation of basic discoveries in cytokine biology to multiple successful biological agents (mAbs and recombinant fusion proteins) that target cytokines. These targeted therapies have not only fundamentally changed the face of multiple immune‐mediated diseases but have also unequivocally established the role of specific cytokines in human disease; cytokine biologists have many times over provided remarkable basic advances with direct clinical benefit. Numerous cytokines rely on the JAK‐STAT pathway for signaling, and new, safe, and effective small molecule inhibitors have been developed for a range of disorders. In this review, we will briefly summarize basic discoveries in cytokine signaling and briefly comment on some major unresolved issues. We will review clinical data pertaining to the first generation of JAK inhibitors and their clinical indications, discuss additional opportunities for targeting this pathway, and lay out some of the challenges that lie ahead. Abstract : Review on first generation of JAK inhibitors, including opportunities for targeting this pathway and some of the challenges that lie ahead.